Yestar Healthcare Holdings Co Ltd (2393) AI Stock Analysis

• Market Cap: HK$298.19M
• Dividend Yield: N/A
• Average Volume (3M): 3.80M
• Price to Earnings (P/E): 0.3
• Beta (1Y): 0.70
• Revenue Growth: 6.10%
• EPS Growth: -115.12%
• Country: HK
• Employees: 627
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): <0.01
• Shares Outstanding: 2,331,590,000
• 10 Day Avg. Volume: 3,306,140
• 30 Day Avg. Volume: 3,797,880
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

Yestar Healthcare Holdings is struggling with financial instability, characterized by declining revenues and profitability, high leverage, and negative cash flow. Technical indicators also reflect bearish momentum, and valuation metrics are poor with a negative P/E ratio. These factors collectively result in a low overall stock score.

Yestar Healthcare Holdings Co Ltd Business Overview & Revenue Model

Company Description

Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. It operates through two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells Fujifilm color photographic paper, industrial NDT X-ray films, and PWB films; and trades in imaging equipment. Its products are used in professional and minilabs; and industrial imaging applications. This segment provides NDT X-ray films under the Yes!Star brand. The Medical Products and Equipment segment manufactures and sells medical dry and wet films, and dental films; and sells medical equipment and diagnostic reagents. The company also distributes in vitro diagnostic products. In addition, it engages in the biotechnology development activities; management of supply chain activities; and provision of freight transportation services. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Yestar Healthcare Holdings Co Ltd generates revenue through the manufacturing and distribution of medical imaging products and in vitro diagnostic (IVD) consumables. Its revenue streams include the sale of X-ray films, imaging equipment, and IVD products to hospitals, clinics, and diagnostic laboratories. The company also engages in partnerships with leading medical equipment manufacturers to expand its product offerings and enhance its market presence. Additionally, Yestar may derive income from providing after-sales support and maintenance services for the products it distributes.

Yestar Healthcare Holdings Co Ltd Financial Statement Overview

Summary

Yestar Healthcare Holdings is facing significant financial challenges including declining revenues, deteriorating profitability, high leverage, and inconsistent cash flow generation. The financials are weak, with a notably poor balance sheet and cash flow situation.

Income Statement

Yestar Healthcare Holdings has experienced significant revenue volatility with a declining trend from 2019 to 2024. The gross profit margin has deteriorated from 25.8% in 2019 to 16.6% in 2024, indicating reduced profitability. The net profit margin has shown improvement, turning positive in 2024, but is largely due to a significant one-time gain rather than operational performance. EBIT and EBITDA margins have also decreased, reflecting operational challenges.

Balance Sheet

The company has a weak balance sheet characterized by negative stockholders' equity in recent years, indicating potential financial distress. The Debt-to-Equity ratio is not meaningful given the negative equity, suggesting high leverage. Despite a positive shift in equity in 2024, the overall financial stability remains questionable with a low equity ratio.

Cash Flow

Cash flow performance has been inconsistent, with operating cash flow declining from 2020 to 2024 and free cash flow turning negative. The operating cash flow to net income ratio is not meaningful for 2024 due to zero operating cash flow. The company has struggled to generate sustainable free cash flow, impacting its financial flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.41B	2.91B	4.29B	4.93B	4.11B
Gross Profit	399.20M	512.78M	708.71M	848.70M	806.88M
EBITDA	-51.93M	376.81M	19.13M	315.89M	-317.26M
Net Income	921.61M	-13.89M	-992.23M	3.33M	-590.49M
Balance Sheet
Total Assets	1.43B	3.43B	3.37B	4.56B	4.66B
Cash, Cash Equivalents and Short-Term Investments	151.78M	251.56M	418.15M	751.77M	687.13M
Total Debt	316.90M	1.63B	1.90B	1.79B	1.84B
Total Liabilities	921.84M	3.82B	3.71B	3.73B	3.80B
Stockholders Equity	461.60M	-457.50M	-408.87M	755.23M	757.04M
Cash Flow
Free Cash Flow	-26.45M	294.22M	-115.58M	665.55M	591.92M
Operating Cash Flow	12.72M	387.67M	-91.73M	715.22M	670.73M
Investing Cash Flow	380.42M	-89.82M	-18.72M	-47.67M	-37.21M
Financing Cash Flow	-502.63M	-234.37M	-180.86M	-654.20M	-604.74M

Yestar Healthcare Holdings Co Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2393, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.15, and above the 200-day MA of 0.10, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.35 is Neutral, neither overbought nor oversold. The STOCH value of 24.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2393.

Yestar Healthcare Holdings Co Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1696	75 Outperform	HK$2.48B	15.47	5.41%	2.38%	-3.32%	-12.94%
1612	74 Outperform	HK$623.49M	6.99	11.96%	4.32%	17.93%	36.82%
1763	73 Outperform	HK$5.08B	11.09	―	2.52%	13.59%	6.31%
6118	52 Neutral	HK$527.96M	13.92	2.03%	―	-2.77%	―
2170	47 Neutral	HK$836.99M	-3.25	-20.74%	―	11.43%	4.88%
2393	41 Neutral	HK$298.19M	0.31	-29.79%	―	6.10%	-115.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Yestar Healthcare Holdings Co Ltd Corporate Events

Yestar Healthcare Reports Significant Decline in Interim Profits

Yestar Healthcare Holdings Co Ltd announced its unaudited interim results for the six months ending June 30, 2025. The company reported a significant decrease in revenue and profit compared to the same period in 2024, with revenue dropping from RMB 1,273,785,000 to RMB 802,634,000 and profit before income tax falling from RMB 1,112,323,000 to RMB 21,152,000. The results indicate a challenging period for the company, impacting its financial performance and potentially its market positioning.

Yestar Healthcare Schedules Board Meeting to Review Interim Results

Yestar Healthcare Holdings Co Ltd has announced a board meeting scheduled for August 29, 2025, to review and approve the unaudited consolidated interim results for the first half of 2025. The meeting will also consider the declaration of an interim dividend, which could have implications for the company’s financial strategy and shareholder returns.

Yestar Healthcare Issues Profit Warning Amid Revenue Decline

Yestar Healthcare Holdings Co Ltd has issued a profit warning, indicating a substantial decrease in net profit for the first half of 2025 compared to the same period in 2024. The decline is attributed to the absence of a one-time profit from senior notes redemption and reduced revenue from its medical products segment. The company advises caution to shareholders and potential investors as it finalizes its unaudited results, with a detailed announcement expected by the end of August 2025.

Yestar Healthcare Announces Change in Share Registrar

Yestar Healthcare Holdings Co Ltd announced a change in its Hong Kong Share Registrar and Transfer Office, effective from 14 July 2025. The new registrar will be Tricor Investor Services Limited, which will handle all applications for registration and transfer of shares from this date. This change is part of the company’s ongoing efforts to streamline its operations and improve shareholder services.

Yestar Healthcare Updates Board Nomination Committee

Yestar Healthcare Holdings Co Ltd announced a change in the composition of its Board’s Nomination Committee, with Ms. Liao Changxiang replacing Mr. Zhao Ziwei as a member, effective June 27, 2025. This change aligns with the amended Corporate Governance Code, ensuring compliance with updated regulations and maintaining a majority of independent non-executive directors on the committee.

Yestar Healthcare Announces Board Composition and Committee Roles

Yestar Healthcare Holdings Co Ltd has announced the composition of its board of directors and the roles within its four board committees. This organizational update is crucial for stakeholders as it outlines the leadership structure and governance, which can impact the company’s strategic direction and operational efficiency.

Yestar Healthcare Enhances Governance with New Nomination Committee Terms

Yestar Healthcare Holdings Co Ltd has outlined the terms of reference for its Nomination Committee, which is responsible for developing and implementing the nomination policy for the company’s board of directors. The committee, composed mainly of independent non-executive directors, will ensure compliance with the Hong Kong Stock Exchange’s listing rules, including director rotation and re-election requirements. This initiative is expected to enhance corporate governance and transparency, potentially impacting stakeholder confidence and the company’s market positioning.